IDH mutations in cancer and progress toward development of targeted therapeutics.
about
Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.Molecular mechanism of the allosteric regulation of the αγ heterodimer of human NAD-dependent isocitrate dehydrogenase.Genetic aberrations and molecular biology of skull base chordoma and chondrosarcoma.2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.A novel approach for the identification of efficient combination therapies in primary human acute myeloid leukemia specimens.The opposite prognostic effect of NDUFS1 and NDUFS8 in lung cancer reflects the oncojanus role of mitochondrial complex IThe β and γ subunits play distinct functional roles in the α2βγ heterotetramer of human NAD-dependent isocitrate dehydrogenase.Prognostic and diagnostic potential of isocitrate dehydrogenase 1 in esophageal squamous cell carcinoma.The clinical significance of isocitrate dehydrogenase 2 in esophageal squamous cell carcinoma.Echo-planar spectroscopic imaging with dual-readout alternated gradients (DRAG-EPSI) at 7 T: Application for 2-hydroxyglutarate imaging in glioma patients.Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis.Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions.Inhibition of malic enzyme 1 disrupts cellular metabolism and leads to vulnerability in cancer cells in glucose-restricted conditions.Regional tumour glutamine supply affects chromatin and cell identity.A chemical probe toolbox for dissecting the cancer epigenome.The Process and Regulatory Components of Inflammation in Brain Oncogenesis.Glutamine Metabolism in Cancer: Understanding the Heterogeneity.Metabolic Alterations in Cancer and Their Potential as Therapeutic Targets.IDH1 Associated with Neuronal Apoptosis in Adult Rats Brain Following Intracerebral Hemorrhage.Epigenetics meets metabolism through PHB-mediated histone H3.3 deposition by HIRA.Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of pre-clinical discovery assaysIDH2 Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity.Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant IDH1.Discovery of a novel calcium-sensitive fluorescent probe for α-ketoglutarate.Reverse engineering the cancer metabolic network using flux analysis to understand drivers of human disease.Molecular mechanisms of isocitrate dehydrogenase 1 (IDH1) mutations identified in tumors: The role of size and hydrophobicity at residue 132 on catalytic efficiency.A Survey of the Neuro-Oncology Landscape.The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia.Recurrent ubiquitin B silencing in gynecological cancers establishes dependence on ubiquitin C.Targeting Metabolism for Cancer Therapy.Breast Tumor Resembling Tall Cell Variant of Papillary Thyroid Carcinoma: A Solid Papillary Neoplasm With Characteristic Immunohistochemical Profile and Few Recurrent Mutations.Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia.The crucial role of multiomic approach in cancer research and clinically relevant outcomes.Detection of clonal heterogeneity and targetable mutations in myeloid sarcoma by high-throughput sequencing.Point mutation (R153H or R153C) in Escherichia coli isocitrate dehydrogenase: Biochemical characterization and functional implication.Mutant IDH1 Promotes Glioma Formation In Vivo.Molecular Markers of Therapy-Resistant Glioblastoma and Potential Strategy to Combat Resistance.Molecular pathophysiology of the myelodysplastic syndromes: insights for targeted therapyPharmacokinetics and safety of Enasidenib following single oral doses in Japanese and Caucasian subjects
P2860
Q30235355-EA7F5C83-10A3-469B-97BB-C4D3C57A43E7Q30981922-F44693BA-B483-461C-B100-E03D9FA75917Q33276468-DDC625CE-A8EB-4FDA-B5F2-23C149E4F857Q33698756-2B6D3DD4-9783-4542-86CC-2ADACB7F6108Q36283942-E3468F1E-761B-4AA7-BC24-015C78B62915Q37169023-84D15C37-EDE2-4A24-BF98-72E076211247Q37615380-3FF70EFA-CF60-4D52-8EBF-78B4C2797F61Q37699202-5244713A-B85F-4175-ACA4-91E3E56349E6Q37743530-765835E8-1EC2-448D-814F-F82B22457F72Q38612062-E40456BC-5840-4493-B89C-935E3223BD41Q38664735-509780CD-CCC5-421A-93D0-F6FB392585B4Q38757450-5A80D403-6FDE-4FD9-B1CC-C3F3B920C001Q38792334-A05F5310-798A-467A-A6D0-BB7C0B6CE036Q38798527-00F7961E-5964-4798-A71C-65D32C1CC4C6Q38967726-9D467755-D4D9-4100-9BEC-1CEFD687D3D3Q39147132-2FE90589-B691-4506-91DC-0F4796F5BE10Q39202332-A2694B00-4D4A-4BDE-BFC1-EB5DE12791BCQ39230796-DECE3667-C155-431E-A60C-7591D35A1182Q39340415-9D430D97-BDDD-400B-A900-9AE1D382B6CAQ39446519-92877DC1-DC3E-40EF-BFDD-87C863B60EEFQ42342118-40C105DD-63F1-4EF2-B41B-D8EBEF0F7A8BQ42371843-4BABAD3B-3AE2-4F2A-A94F-83EDE477B8E1Q45048187-04D35C95-A136-496A-AE2C-A284B565F360Q46232869-80E5D3D8-3FD5-4A88-9A75-D03C2DD381DEQ46335142-007C732D-DC03-4C64-A507-F6E598EC45C6Q46614710-2323E37F-00D6-48A0-A823-9678E734EEC3Q46719423-64FC5DA8-33D1-415F-83FD-3B7F1B527CD1Q47431855-46F9C673-922F-490A-B2D7-4D38FD2CBD45Q47579728-FA4F58BF-C220-4BD5-88FC-B3970395DE60Q47581752-F7E04174-A664-4284-98F5-AB79535CCCF5Q47646742-9D5E93E9-4FC2-4EF6-871A-4B4CF9E628CDQ51072237-CF4F623F-0959-4A88-B354-A38F0ED439DFQ51139133-9F43DE2C-DB3E-4689-9519-1ABB8838C774Q52363678-0C756846-5FFA-4627-B8AD-B8236610A288Q53791265-C5371BF3-7942-4EE4-8F6E-C99E34195707Q54503723-B76C048F-02BE-46F8-9588-447FEA2C9AA7Q55457207-BE4B6F62-AB04-4B82-8F62-AC103543CFCCQ55663256-78329EDB-F276-4403-9221-434CA0A6D55DQ57795839-F3A8DC9B-4E92-42AA-948C-BCB98F6DAE66Q58577222-A3D48B07-7AA8-44BB-B6C7-6312E1702AAF
P2860
IDH mutations in cancer and progress toward development of targeted therapeutics.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
IDH mutations in cancer and progress toward development of targeted therapeutics.
@en
type
label
IDH mutations in cancer and progress toward development of targeted therapeutics.
@en
prefLabel
IDH mutations in cancer and progress toward development of targeted therapeutics.
@en
P2093
P2860
P356
P1433
P1476
IDH mutations in cancer and progress toward development of targeted therapeutics.
@en
P2093
P2860
P304
P356
10.1093/ANNONC/MDW013
P577
2016-04-01T00:00:00Z